Following publication of a safety update by MHRA regarding reports of osteonecrosis of the external auditory canal, the shared care guideline for denosumab (Prolia®) has been updated.
The updated guideline, available here, contains amended advice for healthcare professionals regarding the possibility of osteonecrosis of the external auditory canal which should be considered in patients receiving denosumab who present with ear symptoms including chronic ear infections or in those with suspected cholesteatoma.